Olympus Partners with Gore to Enhance EndoTherapy Offerings in Global Markets
In a strategic move aimed at enhancing patient care in gastrointestinal treatments, Olympus Corporation has recently announced a significant international distribution agreement with W. L. Gore & Associates, Inc. This collaboration will enable Olympus to market the GORE® VIABIL® Biliary Endoprosthesis, an innovative fully covered self-expanding metal stent designed for endoscopic applications. The partnership not only allows Olympus to serve as the exclusive global distributor of this advanced medical device but also positions both companies to leverage their respective strengths in medical technology and product innovation.
The GORE® VIABIL® stent plays a crucial role in managing symptoms associated with biliary strictures, which can arise from various medical conditions, including cancers affecting the biliary tree. Designed to provide a secure and durable barrier against tumor ingrowth, the VIABIL stent features a unique nonporous ePTFE/FEP lining that enhances its effectiveness while maintaining usability. It also boasts a non-foreshortening design, simplifying the deployment process for healthcare professionals.
Olympus will initiate commercialization efforts across Europe with plans to expand to other international markets gradually. This expansion is particularly significant as the gastrointestinal metal stent market continues to grow, driven by an increasing demand for minimally invasive treatment options. The introduction of the GORE® VIABIL® Biliary Endoprosthesis expands Olympus's already comprehensive hepatopancreatobiliary (HBP) portfolio, which is recognized for its pioneering stents tailored to improve patient outcomes.
“This partnership represents a pivotal moment in Olympus's journey to providing top-notch healthcare solutions,” said Mike Callaghan, Global SVP/General Manager of EndoTherapy for Olympus. “Our shared commitment with Gore to innovation in the medical field aligns perfectly with our goal of elevating the standard of care for patients globally.”
Moreover, Gore’s expertise in materials science and innovative product development will complement Olympus's extensive experience in healthcare solutions. With more than 13,000 associates, Gore has a long history of tackling complex challenges across diverse industries, including healthcare. This collaboration will allow both companies to develop solutions that are specifically designed to cater to the evolving needs of patients and healthcare professionals around the world.
Jake Goble, the Cardiac and Surgical Solutions Business Leader at Gore, echoed Callaghan's sentiments, stating, “We believe that the commercial strengths of Olympus's EndoTherapy division, combined with Gore’s innovative capabilities, will significantly benefit patients seeking effective solutions for their gastrointestinal health.”
As the healthcare landscape continues to evolve, partnerships such as this one are crucial for developing advanced treatments that ensure patient comfort and improve clinical outcomes. The introduction of the GORE® VIABIL® stent into Olympus's product range could potentially change the way healthcare providers approach biliary obstruction issues, offering more effective options to manage this challenging condition.
In summary, the strategic alliance between Olympus and W. L. Gore & Associates is set to redefine standards in gastrointestinal therapy. By harnessing their combined expertise and innovative technologies, the two companies are well-positioned to deliver groundbreaking solutions that enhance patient care and improve treatment experiences globally. This collaboration represents a significant step forward in Olympus’s ongoing mission to make people’s lives healthier, safer, and more fulfilling, while continuing to innovate in the medical technology space.
The GORE® VIABIL® stent plays a crucial role in managing symptoms associated with biliary strictures, which can arise from various medical conditions, including cancers affecting the biliary tree. Designed to provide a secure and durable barrier against tumor ingrowth, the VIABIL stent features a unique nonporous ePTFE/FEP lining that enhances its effectiveness while maintaining usability. It also boasts a non-foreshortening design, simplifying the deployment process for healthcare professionals.
Olympus will initiate commercialization efforts across Europe with plans to expand to other international markets gradually. This expansion is particularly significant as the gastrointestinal metal stent market continues to grow, driven by an increasing demand for minimally invasive treatment options. The introduction of the GORE® VIABIL® Biliary Endoprosthesis expands Olympus's already comprehensive hepatopancreatobiliary (HBP) portfolio, which is recognized for its pioneering stents tailored to improve patient outcomes.
“This partnership represents a pivotal moment in Olympus's journey to providing top-notch healthcare solutions,” said Mike Callaghan, Global SVP/General Manager of EndoTherapy for Olympus. “Our shared commitment with Gore to innovation in the medical field aligns perfectly with our goal of elevating the standard of care for patients globally.”
Moreover, Gore’s expertise in materials science and innovative product development will complement Olympus's extensive experience in healthcare solutions. With more than 13,000 associates, Gore has a long history of tackling complex challenges across diverse industries, including healthcare. This collaboration will allow both companies to develop solutions that are specifically designed to cater to the evolving needs of patients and healthcare professionals around the world.
Jake Goble, the Cardiac and Surgical Solutions Business Leader at Gore, echoed Callaghan's sentiments, stating, “We believe that the commercial strengths of Olympus's EndoTherapy division, combined with Gore’s innovative capabilities, will significantly benefit patients seeking effective solutions for their gastrointestinal health.”
As the healthcare landscape continues to evolve, partnerships such as this one are crucial for developing advanced treatments that ensure patient comfort and improve clinical outcomes. The introduction of the GORE® VIABIL® stent into Olympus's product range could potentially change the way healthcare providers approach biliary obstruction issues, offering more effective options to manage this challenging condition.
In summary, the strategic alliance between Olympus and W. L. Gore & Associates is set to redefine standards in gastrointestinal therapy. By harnessing their combined expertise and innovative technologies, the two companies are well-positioned to deliver groundbreaking solutions that enhance patient care and improve treatment experiences globally. This collaboration represents a significant step forward in Olympus’s ongoing mission to make people’s lives healthier, safer, and more fulfilling, while continuing to innovate in the medical technology space.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.